Today: 5 November 2025
Subscribe
Browse Tag

breakthrough

From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

Company Overview: AI-Powered Biotech at the Intersection of Therapeutics & Biodefense Lunai Bioworks Inc. is a pre-clinical stage biotechnology company pioneering an unusual dual focus: AI-driven drug discovery and biodefense. The company’s mission is to “capture biological signals at scale, decode them with AI, and rapidly validate insights in model systems”, bridging cutting-edge computation with experimental biotech ainvest.com ainvest.com. In practical terms, Lunai is developing both therapeutic platforms (for diseases like cancer and neurodegeneration) and advanced diagnostics/screening tools (including detecting chemical/biological threats), all underpinned by machine learning. Core Technology & Pipeline: Lunai’s flagship approach is a next-generation allogeneic dendritic cell
5 November 2025
 ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

RANI Stock Performance: From Penny Stock to Momentum Rocket Rani Therapeutics’ stock price has been on a tear in late 2025, turning heads in the biotech investing community. After languishing under $1 for most of the year, RANI exploded upward in October. It closed on Oct 31 at $2.20, up +51.7% in one day finviz.com on massive volume (~61 million shares vs ~15 million average finviz.com). In fact, over the past month RANI has climbed about 335% finviz.com. Just a few weeks ago in early October it was trading around 50–60 cents; by the first week of November it’s oscillating
3 November 2025
 ·  ·  ·  ·  · 
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Stock Rally on Novel Cancer Data Intensity Therapeutics (NASDAQ: INTS) has been one of the market’s biggest movers. On Oct. 30, 2025 its stock was around $0.27 per share investing.com – an 84% drop YTD but up nearly 200% intraday on the news of its Lancet-published trial tipranks.com. Trading volume exploded: ~279 million shares traded on Oct. 30 vs. an average of ~5 M per day tipranks.com. The rally was sparked by the Phase 1/2 study announcement that Intensity’s lead drug, INT230‑6, showed striking tumor control in advanced cancer. The study covered 64 patients across 20+ tumor types – most had failed multiple therapies.
30 October 2025
 ·  ·  ·  ·  · 
Rigetti’s (RGTI) Quantum Stock Skyrockets 5,000% – Bubble or Breakthrough Ahead?

Rigetti’s (RGTI) Quantum Stock Skyrockets 5,000% – Bubble or Breakthrough Ahead?

Rigetti’s stock chart has resembled a rocket ship: exploding out of penny-stock territory to multi-billion-dollar market cap in 2025. Experts stress that the company needs to start matching hype with revenue growth to sustain this valuation ts2.tech ts2.tech. Market Mania: Parabolic Rise and Recent Pullback Rigetti’s stock journey in 2025 has been nothing short of extraordinary. At the start of the year RGTI traded below $1; by Oct. 15 it hit an all-time high around $56.34 ts2.tech. (For context, TS2 notes that “all-time high of around $56” after a ~5,000% rally ts2.tech.) However, after peaking in mid-October the stock has
27 October 2025
 ·  ·  ·  ·  · 
QuantumScape (QS) Stock Skyrockets 14% on Solid-State EV Battery Breakthrough – Can the Rally Continue?

QuantumScape Stock Soars on Solid-State Battery Breakthrough – 3-Day Rally and Sector Shake-Up

Recent Stock Surge and Technical Picture QuantumScape’s stock went into blast-off mode at the start of October 2025. After hovering around $12–13 through mid-September, shares broke out on a string of positive developments. The stock jumped 18% on Sept 18 and another +18.4% on Oct 1 ts2.tech. By Oct 3, QS hit an intraday high of $16.49 (just above its prior 52-week peak ~$16.45) before finishing at $15.92 finviz.com. This price level marks a stunning ~+172% gain year-to-date ts2.tech, vastly outperforming broader markets and making QS one of 2025’s top tech movers. Trading activity has been frenzied – tens of
6 October 2025
 ·  ·  ·  ·  · 
QuantumScape (QS) Stock Skyrockets 14% on Solid-State EV Battery Breakthrough – Can the Rally Continue?

QuantumScape Rockets 11% to $15.92 on Solid-State Battery Breakthroughs

Stock Performance and Recent Moves QuantumScape shares have soared in recent days, reflecting renewed investor optimism in its solid-state battery roadmap. On Oct. 1 (Wednesday) after markets closed, QS jumped 18.43% to a $14.59 close investing.com, driven by news of the Corning partnership (announced Sept. 30). The rally continued into the week’s end: by market close Oct. 3 (Friday), QS hit $15.92 (+11.33%), setting a fresh 52-week high. (Intraday high was about $16.49 investing.com.) Benzinga noted the stock’s “impressive climb” on Oct. 3, with volume well above average and a breakout past resistance near $14.70 benzinga.com benzinga.com. Year-to-date, QS is up roughly +150–200%, far outperforming the
3 October 2025
 ·  ·  ·  ·  ·  · 
Rigetti Computing’s Quantum Leap: Stock Soars on Breakthroughs and Bold Bets

Rigetti (RGTI) Stock Soars on New Quantum Wins — Breakthrough or Bubble?

Stock Price Movement Rigetti’s stock trajectory has been nothing short of dramatic. After languishing below $1 in 2023, RGTI took off in summer 2025. By mid-September it had “soared more than 80% in the past month and 160% in the last three months,”according to TipRanks tipranks.com. It reached an intraday 52-week high ~$34.40 in late Sept reuters.com. On Oct 2 it opened around $30.67 and climbed to trade near $35 early in the session (+17% intraday) stockanalysis.com; Reuters shows it at ~$31.95 (up +7.07%) later that morning reuters.com. In the days prior, the stock had run up on both good news and broader
2 October 2025
 ·  ·  ·  ·  ·  · 
CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

Breaking the Genetic “Spell” of a Liver Disease Phenylketonuria (PKU) is a hereditary metabolic liver disorder where a single DNA typo disrupts the PAH enzyme that breaks down phenylalanine, an amino acid nature.com fiercebiotech.com. Without a working PAH enzyme, phenylalanine builds up to toxic levels, causing brain damage, intellectual disability, and seizures if untreated. Newborn screening identifies PKU early, and patients are put on a strict lifetime diet limiting protein (to keep blood Phe 120–360 µM) pennmedicine.org fiercebiotech.com. Even with dietary control and medications, many patients struggle – foods high in protein are largely off-limits, and even newer drugs like
15 September 2025
 ·  ·  ·  · 
Quantum Tech Leap: Breakthroughs, Billion‑Dollar Bets & Bold Moves (July 23–24, 2025)

Quantum Tech Leap: Breakthroughs, Billion‑Dollar Bets & Bold Moves (July 23–24, 2025)

On July 23, 2025, French researchers led by Eleni Diamanti published a protocol in PRX Quantum to quantify the accuracy of quantum information transmissions with untrusted devices, enabling verification of entangled photon messages even with simulated loss and attacks while preserving quantum data. Two independent groups reported that diamond-based quantum sensors could operate more than 100 sensor qubits in parallel using NV-center diamonds, marking a ninefold increase toward scalable quantum sensing. On July 24, 2025, SuperQ Quantum Computing Inc. announced its first commercial revenue from a project with D-Wave and Verge Ag to optimize route planning for autonomous farm robots
24 July 2025
 ·  ·  ·  ·  ·  · 
Go toTop